Abbott starts pivotal study for Cephea mitral valve replacement
Abbott has started a pivotal study for its Cephea mitral valve replacement.
Related stories
Nikkei Falls 3% as Technology Shares Slide on AI Concerns
The Nikkei fell 3% as technology shares declined amid concerns about artificial intelligence.
M impact | EQUITY | Oct 30, 2026, 02:50 AM UTC
Australian Gold Stocks Snap Four-Day Winning Streak as Bullion Slides
Australian gold stocks ended a four-day winning streak as bullion prices fell amid bets on a Federal Reserve rate hike.
M impact | EQUITY | Oct 30, 2026, 02:48 AM UTC
Cyera Has Spoken to Investors About Raising Capital at $20 Billion Valuation
Cyera has spoken to investors about a capital raise that would nearly double its valuation to $20 billion, The Information reports.
M impact | EQUITY | Oct 30, 2026, 02:47 AM UTC
AIA Shares Rise 3.98% to One-Month High
AIA shares rose 3.98% intraday, their highest since Sept. 30. Goldman Sachs expects new business value growth to resume.
M impact | EQUITY | Oct 30, 2026, 02:47 AM UTC
Keytruda SC Quarterly Sales Reach a New Milestone
Quarterly sales of Keytruda SC, which uses Alteogen’s technology, surpassed the stated threshold for the first time.
M impact | EQUITY | Oct 30, 2026, 02:39 AM UTC
闻泰科技 hits limit-up after confidentiality arrangement with Nexperia administrator
China’s Wingtech Technology rose to its daily limit after announcing a confidentiality arrangement with Nexperia’s administrator regarding negotiations.
M impact | EQUITY | Oct 30, 2026, 02:38 AM UTC